Verrica Pharmaceuticals Inc.

The company is a therapeutics company that develops and commercializes medications for dermatologic diseases, including skin cancers. Its current commercial product and pipeline candidates are clinician-administered therapies. The product portfolio includes one approved product for molluscum contagiosum, or molluscum, with potential for additional indications, and other pipeline candidates. Its commercial product, YCANTH (VP-102), received U.S. Food and Drug Administration (FDA) approval in July 2023 for treating molluscum in adult and pediatric patients two years of age and older. YCANTH (VP-102) is a proprietary drug-device combination containing a GMP-controlled formulation of cantharidin. The company is developing YCANTH (VP-102) for a potential follow-on indication for common warts. Its second development candidate, VP-315 (ruxotemitide), is an oncolytic peptide-based injectable therapy for dermatology oncologic conditions, including basal cell carcinoma (BCC). The company is focusing its efforts and financial resources on the commercialization of YCANTH (VP-102) for molluscum, the development of YCANTH (VP-102) for common warts, and the development of VP-315 for BCC. YCANTH (VP-102) (cantharidin) 0.7% topical solution was the first FDA-approved product for molluscum on July 21, 2023. The company commercially launched YCANTH (VP-102) in August 2023 in the United States. As of December 31, 2025, it has a specialized sales organization of approximately 40 field employee sales representatives in the United States, targeting pediatric dermatologists, dermatologists, pediatricians, and select other primary care healthcare providers. Molluscum is a contagious skin disease caused by a pox virus, typically presenting with 10 to 30 lesions, and sometimes over 100 lesions.